Oxytocin

Scientific identity: Oxytocin is a cyclic nonapeptide with the amino acid sequence Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂. The two cysteine residues at positions 1 and 6 form a disulfide bridge that creates the characteristic cyclic ring structure essential for oxytocin receptor binding. The C-terminal glycine amide is also required for full biological activity. Synthetic oxytocin replicates this structure exactly and is indistinguishable from the endogenous peptide by standard analytical methods.

Primary research target: Oxytocin receptor (OXTR) — a class A G protein-coupled receptor coupled primarily to Gαq/11, mediating phospholipase C activation, IP₃ production, and intracellular calcium mobilisation. OXTR is expressed in the brain, uterus, mammary gland, heart, kidney, and other peripheral tissues.

Research areas: Oxytocin receptor pharmacology, social behaviour neuroscience, neuroendocrine regulation, hypothalamic-pituitary biology, neuropeptide signalling, peripheral tissue physiology research, cardiovascular biology research.

Product quantity. 10mg per vial

Purity: Greater than 99%, confirmed by HPLC and LC-MS analysis at the batch level.

Analytical documentation: A batch-specific Certificate of Analysis is available on the Longevia Research website, covering compound identity, purity, and lot traceability.

Research-use classification: For laboratory research use only. Not for human or veterinary use, clinical diagnostics, or any in-vivo application in humans outside of regulated research settings.

Oxytocin Receptor Biology

Oxytocin exerts its effects primarily through the oxytocin receptor (OXTR), a class A GPCR coupled to Gαq/11. Receptor activation triggers phospholipase C-mediated IP₃ production and intracellular calcium release — a signalling cascade studied across uterine smooth muscle, central neuronal, and peripheral tissue models. OXTR is also capable of coupling to Gαi in certain cell contexts, and receptor dimerization with vasopressin receptors (V1aR, V1bR) has been characterised in experimental systems. These receptor biology findings provide the mechanistic foundation for oxytocin's broad research utility.

Relationship to Vasopressin

Oxytocin and arginine vasopressin (AVP) are structurally related neurohypophysial peptides sharing seven of nine amino acid positions. Both are produced in hypothalamic nuclei and released from the posterior pituitary. Their receptors — OXTR, V1aR, V1bR, V2R — show cross-reactivity at higher concentrations in experimental systems, a pharmacological consideration relevant to receptor selectivity research. Studies examining oxytocin-specific effects must account for potential vasopressin receptor engagement, particularly in peripheral tissue models.

Social Behaviour and Neuroscience Research

Oxytocin has been extensively investigated in animal models of social behaviour, including studies examining pair bonding, affiliative behaviour, social recognition, and parental behaviour in rodent systems. These studies have used central and peripheral oxytocin administration in defined animal models; findings are species- and context-specific. Human observational and interventional research has examined intranasal oxytocin administration in relation to social cognition and interpersonal behaviour parameters. These human findings come from specific study designs with varied outcomes across the literature and do not establish that oxytocin produces defined social effects in all contexts.

Neuroendocrine and Peripheral Research

Beyond central neuroscience, oxytocin research has examined peripheral OXTR signalling in uterine smooth muscle, cardiac tissue, the gastrointestinal tract, and adipose tissue in experimental systems. These peripheral research areas reflect the broad tissue distribution of OXTR and represent distinct research questions from central behavioural studies. Findings from one tissue system should not be generalised across all OXTR-expressing contexts.

Reliable research begins with accurately characterised material. For a cyclic nonapeptide such as oxytocin, that means confirming sequence integrity, disulfide bridge formation, and purity at the batch level — because reduced (ring-open) oxytocin or truncated sequences are biologically distinct from the intact cyclic peptide and can confound receptor binding and signalling assays.

Purity assessment: Each production lot is characterised to greater than 99% purity by high-performance liquid chromatography (HPLC). Chromatographic purity data is reported on the batch Certificate of Analysis.

Identity confirmation: Peptide identity and disulfide bridge integrity are confirmed by mass spectrometry (LC-MS), providing molecular-weight verification consistent with the cyclic, disulfide-bonded form. HPLC and LC-MS data together confirm that the material supplied corresponds to the labelled compound at the labelled purity.

Batch traceability and Certificate of Analysis: Every vial of Oxytocin 10mg is traceable to a specific production lot. A batch-specific Certificate of Analysis is accessible directly on the Longevia Research website, covering purity, identity, and lot information. Researchers evaluating this material for assay work are encouraged to review the current batch documentation before use, since analytical specifications are applied at the lot level.

Handling: This material should be handled by qualified personnel using appropriate laboratory technique and personal protective equipment, consistent with institutional protocols for research-grade neuropeptides.

Longevia Research supplies Oxytocin 10mg for laboratory and in-vitro research use only. The product is intended for use by qualified researchers and trained laboratory personnel in appropriate controlled research environments.

Oxytocin is a synthetic research peptide supplied strictly as a research tool. It is not a drug, not a dietary supplement, not a food or food ingredient, and not a cosmetic. While pharmaceutical oxytocin formulations hold regulatory approval for specific clinical indications, no such approval applies to this Longevia Research vial, which is not a pharmaceutical product and has not been evaluated by any regulatory authority for safety or efficacy in this formulation.

Longevia provides no dosing instructions, administration guidance, treatment protocols, or reconstitution recommendations for this compound. The scientific literature summarised on this product page describes experimental observations in defined cell-based, tissue, animal, and human research systems. Those findings are not medical claims and should not be interpreted as evidence of human efficacy, human safety, or fitness for any clinical application from this product.

The purchaser assumes full responsibility for lawful acquisition, handling, storage, use, and disposal of this material, and for compliance with all applicable local, state, federal, and institutional regulations. By purchasing this product, the buyer confirms that it will be used solely for legitimate laboratory research purposes by qualified personnel, and that its acquisition and intended use comply with applicable laws in the buyer's jurisdiction.